Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to -$3.5 million.

  • Gyre Therapeutics' Change in Accured Expenses fell 12708.47% to -$3.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $654000.0, marking a year-over-year increase of 13124.7%. This contributed to the annual value of -$1.5 million for FY2024, which is 20352.7% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Change in Accured Expenses of -$3.5 million as of Q3 2025, which was down 12708.47% from -$2.4 million recorded in Q2 2025.
  • In the past 5 years, Gyre Therapeutics' Change in Accured Expenses ranged from a high of $6.2 million in Q4 2022 and a low of -$5.2 million during Q4 2021
  • Its 5-year average for Change in Accured Expenses is -$171105.3, with a median of -$31000.0 in 2021.
  • As far as peak fluctuations go, Gyre Therapeutics' Change in Accured Expenses skyrocketed by 344193.55% in 2022, and later plummeted by 327571.43% in 2025.
  • Gyre Therapeutics' Change in Accured Expenses (Quarter) stood at -$5.2 million in 2021, then soared by 220.92% to $6.2 million in 2022, then plummeted by 76.06% to $1.5 million in 2023, then soared by 39.95% to $2.1 million in 2024, then tumbled by 268.25% to -$3.5 million in 2025.
  • Its last three reported values are -$3.5 million in Q3 2025, -$2.4 million for Q2 2025, and $4.4 million during Q1 2025.